Liu, Y.; Zhou, Y.-Q.; Nie, L.; Zhu, S.-S.; Li, N.; Wu, Z.-H.; Wang, Q.; Qi, J.; Wu, B.-Y.; Chen, S.-Q.;
et al. BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma. Cancers 2023, 15, 5774.
https://doi.org/10.3390/cancers15245774
AMA Style
Liu Y, Zhou Y-Q, Nie L, Zhu S-S, Li N, Wu Z-H, Wang Q, Qi J, Wu B-Y, Chen S-Q,
et al. BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma. Cancers. 2023; 15(24):5774.
https://doi.org/10.3390/cancers15245774
Chicago/Turabian Style
Liu, Ying, Ya-Qiong Zhou, Lei Nie, Shan-Shan Zhu, Na Li, Zhen-Hua Wu, Qi Wang, Jian Qi, Bing-Yuan Wu, Shu-Qing Chen,
and et al. 2023. "BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma" Cancers 15, no. 24: 5774.
https://doi.org/10.3390/cancers15245774
APA Style
Liu, Y., Zhou, Y. -Q., Nie, L., Zhu, S. -S., Li, N., Wu, Z. -H., Wang, Q., Qi, J., Wu, B. -Y., Chen, S. -Q., & Wang, H. -B.
(2023). BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma. Cancers, 15(24), 5774.
https://doi.org/10.3390/cancers15245774
